Clinical Trials Browser

Phase 2 × Recruiting × polatuzumab vedotin × Clear all

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-04-02

MK-2140-011

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05615636 2026-03-16

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, B-Cell

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07397832 2026-02-09

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05260957 2025-12-31

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Phase 2 Recruiting

Lymphoma, Non-Hodgkin

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06765317 2025-11-26

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06453044 2025-09-24

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06530511 2025-02-04

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06554600 2024-08-15

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05868395 2024-05-29

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT06176729 2023-12-20

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse